(Press-News.org) - The nomination of the new generation of FGFR2/3 inhibitor for the treatment of tissue-agnostic solid tumors, bringing the total number of PCCs nominated by Insilico in 2023 to six.
- ISM8001 is an oral, highly selective, covalent inhibitor that demonstrated superior potency in multiple FGFR2/3-driven efficacy models, and also in gatekeeper and molecular brake mutant resistant models.
- The program once again demonstrates Insilico's ability to efficiently generate novel molecules with high quality that are currently available for partnering.
Insilico Medicine ("Insilico"), a generative artificial intelligence (AI)-driven clinical-stage drug discovery company, today announced the nomination of ISM8001, a novel molecule targeting FGFR2/3 for the treatment of tissue-agnostic solid tumors bringing the total number of PCCs nominated in 2023 to six.
Fibroblast growth factor receptors 2 and 3 (FGFR2/3) are parts of the FGFR family, which play a critical role in several biological processes including cell proliferation/survival, angiogenesis, by involvement in signal transduction pathways. Alterations in FGFR2/3 have been driven force in multiple types of solid tumors, mainly in urothelial carcinoma, intrahepatic cholangiocarcinoma, NSCLC, esophagogastric cancer, colorectal cancer, pancreatic cancer, endometrial cancer, making them potential targets for the treatment of tissue-agnostic solid tumors. However, there are currently limitations with approved pan-inhibitors due to the high proportion of adverse events, suboptimal response, and the acquired drug resistance.
"Clinical Cancer Research reported that FGFR aberrations are present in about 7.1% of cancer patients. Currently, the pan-inhibitors are approved only for UC and ICC indications." said Feng Ren, PhD, co-CEO and Chief Scientific Officer of Insilico Medicine. "Leveraging our pioneering generative AI platform, Insilico has devised a distinct molecular design strategy to tackle current challenges that retain the desired profiles and overcome the drawbacks of previous generations for a broader population with FGFR2/3 aberration."
Insilico generates a series of novel molecules with desired profiles and delivers the new generation of FGFR covalent inhibitor with the support of Chemistry42. ISM8001 is an orally available, highly selective dual inhibitor targeting FGFR2/3, and sparing FGFR1/4. The compound demonstrated superior potency in multiple FGFR2/3-driven efficacy models, and also in gatekeeper and molecular brake mutant-resistant models. It also showed favorable DMPK profiles, low efficacious dose, and desirable safety margin to support higher human dose.
"We anticipate forging collaborations with seasoned partners to propel this program towards the next milestone." said Alex Zhavoronkov, PhD, Founder, and co-CEO of Insilico Medicine. "The nomination of ISM8001 unequivocally validates the capabilities of Pharma.AI, Insilico's integrated generative AI platform. We are committed to persistently upgrading and expanding forefront technologies and AI algorithms, with an ultimate aim to expedite drug discovery pursuits and address unmet clinical needs."
Driven by generative artificial intelligence, Insilico stands at the intersection of artificial intelligence and state-of-art technologies. In 2023, The company achieved 6 wholly-owned preclinical candidate (PCC) nominations empowered by Pharma.AI, bringing the total number of PCCs nominated to 17 since 2021. Furthermore, it has propelled five programs into the clinical stage, inclusive of four in Phase 1 trials, with the most advanced being an anti-fibrosis program currently in Phase 2 trial.
About Insilico Medicine
Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.com
END
Insilico announces the expansion of its oncology pipelines and delivers the new generation FGFR2/3 inhibitor
2023-12-28
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Liso-cel is a cost effective second-line treatment for common form of lymphoma
2023-12-28
(WASHINGTON, Dec. 28, 2023) – Lisocabtagene maraleucel (liso-cel), a CAR T-cell therapy, is a cost effective second line treatment for relapsed and refractory (hard to treat) diffuse large B-cell lymphoma (r/r DLBCL), according to a study published today in Blood Advances. The study is the first of its kind to incorporate healthcare expenses, societal productivity losses, and patient quality of life in assessing the drug’s cost-effectiveness.
"In our study, we incorporated the often-overlooked societal costs associated with cancer treatment, which are typically neglected in ...
A team from the UPV and CSIC discovers a new method for generating metal nanoparticles for use as catalysts
2023-12-28
This new method is based on the exsolution process activated by microwave radiation. Exsolution is a method of generating metallic nanoparticles on the surface of ceramic materials. "At elevated temperatures and in a reducing atmosphere (usually hydrogen), metal atoms migrate from the structure of the material to its surface, forming metal nanoparticles anchored to the surface. This anchoring significantly increases the strength and stability of these nanoparticles, which positively impacts the efficiency of these catalysts," explains Beatriz García Baños, a researcher in the Microwave Area of the ITACA Institute at the UPV.
In the work now ...
Cancer test shows promise for bringing the benefits of immunotherapy to more patients
2023-12-28
Brigham researchers’ findings from next-generation sequencing suggest that revising current cancer care guidelines could allow approximately 6,000 more patients in the U.S. to benefit from immunotherapy treatment each year
Immunotherapy is a highly effective treatment for patients whose cancers harbor mismatch repair deficiency, and a new study identifies more cancer patients who could benefit from this form of therapy. Investigators from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, found that nearly six percent of endometrial cancer patients and one percent of colorectal cancer patients with mismatch repair deficiency were ...
Medicaid coverage of physical, behavioral health together does not improve access, care
2023-12-28
Health care systems in the United States have gradually embraced the concept that mental health should be treated on par with physical health, especially in light of increased rates of anxiety and depression during and after the COVID-19 pandemic.
To improve access to mental health treatment, many Medicaid programs have required their managed care organizations to pay for behavioral health and physical health together. That’s in contrast to the traditional approach in which behavioral health, including treatment for substance use disorders, was “carved out” ...
Scientists discover new way to identify liquid water on exoplanets
2023-12-28
Scientists have devised a new way to identify habitable planets and potentially inhabited planets, by comparing the amount of carbon dioxide in their atmosphere, to neighbouring planets.
An international team of researchers from the University of Birmingham (UK), the Massachusetts Institute of Technology (MIT) (US) and elsewhere, have shown that if a planet has a reduced amount of CO2 in its atmosphere compared to neighbouring planets, it suggests there is liquid water on that planet’s surface. The drop in CO2 levels implies ...
Developing nanocatalysts to overcome limitations of water electrolysis technology
2023-12-28
Green hydrogen can be produced through water electrolysis technology, which uses renewable energy to split water into hydrogen and oxygen without emitting carbon dioxide. However, the production cost of green hydrogen is currently around $5 per kilogram, which is two to three times higher than gray hydrogen obtained from natural gas. For the practical use of green hydroten, the innovation in water electrolysis technology is required for the realization of hydrogen economy, especially for Korea where the utilization ...
Blood poisoning keeping many people out of work
2023-12-28
A few years ago, the World Health Organization estimated that blood poisoning, or sepsis, is involved in one in five deaths in the world. 11 million people die from sepsis each year, of which nearly 3 million are children.
This is also a problem in Norway, with thousands of people affected every year.
“Sepsis is a severe immunological overreaction to an infection. It causes the body’s organs to fail,” says Nina Vibeche Skei. She is a doctoral research fellow at the Norwegian University of Science and Technology (NTNU) and a senior anaesthetist ...
Oral peptides: A new era in drug development
2023-12-28
For decades, a substantial number of proteins, vital for treating various diseases, have remained elusive to oral drug therapy. Traditional small molecules often struggle to bind to proteins with flat surfaces or require specificity for particular protein homologs. Typically, larger biologics that can target these proteins demand injection, limiting patient convenience and accessibility.
In a new study published in Nature Chemical Biology, scientists from the laboratory of Professor Christian Heinis at EPFL have achieved a significant milestone in drug development. Their research ...
Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner
2023-12-28
The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition.
AFCR’s BRACE (Bridging Research from Academia to Cancer Entrepreneurship) Award Venture Competition is designed to support and accelerate oncology innovations on their path toward commercialization, with the ultimate goal of improving outcomes for patients affected by cancer globally. AFCR aims to support the winners of the BRACE Award with funding resources, advisory experts, and access to our global network of key opinion leaders in cancer research.
The winner of the BRACE ...
Social media platforms generate billions in annual ad revenue from US youth
2023-12-27
Embargoed for release: December 27, 2023, 2:00 PM ET
Key points:
Researchers estimated that Facebook, Instagram, Snapchat, TikTok, X (formerly Twitter), and YouTube collectively derived nearly $11 billion in advertising revenue during 2022 from U.S. youth, who are vulnerable to negative mental health outcomes.
The study is the first to offer estimates of the number of youth users on these platforms and how much annual ad revenue is attributable to them.
According to the researchers, the study’s ...